This study will enroll with children, adolescents and young adults that are less than 22 years old that have returned or 'relapsed' acute myeloid leukemia (AML) diagnoses. Within this group, the study is also targeting those are also unable to receive additional chemotherapy treatments containing anthracycline, which is a type of antibiotic that is used to treat many types of cancer and can cause damage to the heart in some children and young adults. The study doctors want to find out how safe the new study drug called venetoclax is when given with three other chemotherapy drugs called...
